Level Zero Health
Level Zero Health is a UK healthtech startup developing a DNA-based biosensor patch and handheld reader for non-invasive, real-time hormone monitoring from interstitial fluid, serving IVF clinics, menopause programs, testosterone therapy providers, and clinical researchers ahead of FDA/CE commercialization.
- Company typePrivate
- Founded2023
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Level Zero Health does
Level Zero Health is a UK-based healthtech startup founded in 2023 that develops DNA-based biosensor technology for non-invasive, real-time hormone monitoring. The company's core platform measures estradiol (E2), progesterone (P4), luteinising hormone (LH), cortisol, and testosterone from interstitial fluid using a single-use patch applied to the skin for 10-15 minutes, paired with a handheld reader. The company reports 98% accuracy across the human clinical range for its biosensors and is pursuing FDA and CE-mark approvals with a targeted market-ready product by 2028.
The technology combines DNA/aptamer-based electrochemical sensing with microfluidic and MEMS engineering, with research roots at Imperial College London. The company is constructing what it describes as the world's largest hormone-health dataset through continuous monitoring, intended to support personalized insights over time. A broad patent covering the DNA-based biosensor platform was filed in 2024, and the founding team includes researchers and engineers drawn from Palantir, Philips, Dyson, Hong Kong Polytechnic, Oxford, and Imperial.
The business model is pre-commercial. Level Zero Health operates a B2B partnership-led go-to-market, targeting IVF clinics, menopause and perimenopause programs, testosterone therapy (TRT) management, and academic/clinical research institutions. It plans to generate revenue through hardware sales (single-use patches) and recurring platform subscriptions for the handheld reader and data service, though pricing is undisclosed pending regulatory clearance. The company is not yet selling; its strongest demand signal to date is $3M in letters of intent from major IVF clinics, alongside a £5.5M ($6.9M) pre-seed round led by Redalpine in February 2025, the largest pre-seed raised by a European female-founded company.
Level Zero Health firmographics
Firmographics- Name
- Level Zero Health
- Legal name
- Level Zero Health
- Website
- https://levelzerohealth.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Level Zero Health is a UK healthtech startup developing a DNA-based biosensor patch and handheld reader for non-invasive, real-time hormone monitoring from interstitial fluid, serving IVF clinics, menopause programs, testosterone therapy providers, and clinical researchers ahead of FDA/CE commercialization.
- Ownership category
- akta.pro rank
Level Zero Health industry classification
Industry- Product category
- Wearable Hormone Biosensor Diagnostics
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Measuring & Controlling Devices, Nec (3829)
- akta.pro primary industry
- Continuous Temperature & Fever Monitoring (Wearable Thermometry) (HLAHACAK)
Keywords
Where Level Zero Health is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Level Zero Health business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Hormone Monitoring Patches: Single-use patches that measure hormones from interstitial fluid, sold to clinical and research organizations. The company has secured $3 million in letters of intent from major IVF clinics.
- Real-time Monitoring Platform: Handheld measurement device platform for remote hormone monitoring targeting hormone-critical markets including IVF, menopause, and testosterone therapy.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Research and Clinical Partnership Program |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels3 records
Level Zero Health product offering
Product offeringCore offering
Level Zero Health develops a DNA-based biosensor platform that enables real-time, non-invasive hormone monitoring through interstitial fluid analysis. The product consists of a single-use skin-worn patch applied for 10–15 minutes, paired with a compact handheld unit that captures and displays the measurement, covering estradiol (E2), progesterone (P4), luteinising hormone (LH), cortisol, and testosterone with 98% accuracy across the human clinical range. The platform targets IVF clinics, menopause research and management programs, testosterone replacement therapy providers, and research institutions studying hormone biology.
Product overview
Level Zero Health offers a hormone monitoring platform consisting of a single-use patch-based diagnostic system and a companion handheld measurement device. The patch is applied to the skin for 10-15 minutes and measures hormones (estradiol, progesterone, LH, cortisol, testosterone) from interstitial fluid, with the handheld unit capturing and displaying results. The company is also developing a wearable continuous monitoring device as a future product. The platform enables lab-free, real-time hormone measurement without blood draws, targeting clinical applications in IVF, menopause, and testosterone therapy management.
Differentiator
Problem solved
Functional benefit
Products and services
- Level Zero Health Hormone Monitoring Patch A single-use wearable patch applied to the skin for 10–15 minutes that uses DNA-based biosensors to measure estradiol (E2), progesterone (P4), luteinising hormone (LH), cortisol, and testosterone from interstitial fluid with 98% accuracy across the human clinical range, paired with a compact handheld reader that captures the measurement. Targeted at IVF clinics, menopause research and management programs, testosterone replacement therapy providers, and research institutions.
- Level Zero Health Hormone Monitoring Platform A biosensor platform that enables real-time, non-invasive hormone monitoring through interstitial fluid analysis using DNA-based sensors and a handheld reader, targeting fertility (IVF), menopause, and testosterone therapy applications. Underpins the build-out of the world's largest hormone-health dataset for personalized insights and supports recurring access via subscription model alongside hardware sales.
Quantifiable outcome
- 98% accuracy across the human clinical range
- +2 more outcomes
Companies that use Level Zero Health
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
Level Zero Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Level Zero Health partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Major IVF ClinicsprimaryLevel Zero Health has secured $3 million in letters of intent from major IVF clinics, indicating strong commercial interest in the hormone monitoring platform for fertility treatment applications.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Level Zero Health competitors and assessment
Company assessmentDirect peers
- Dexcom: Continuous biosensing leader for glucose monitoring. Dexcom is the closest analog for Level Zero's continuous biosensor + consumables business model applied to a new analyte (hormones vs. glucose).
- Mira: At-home fertility hormone tracking (LH, E2, PdG) using a quantitative analyzer and consumable test wands. Targets the same IVF and trying-to-conceive customer base as Level Zero with hormone quantification outside the clinic.
- Natural Cycles: FDA-cleared fertility tracking app combining basal body temperature with hormonal inputs. Operates in the same women's health / reproductive hormone monitoring category as Level Zero's product.
- Modern Fertility: At-home hormone testing (FSH, LH, estradiol, AMH) for fertility insights, acquired by Ro. Targets the same reproductive hormone customer with a different (blood-spot) testing modality.
Broad incumbents
- Abbott: FreeStyle Libre CGM franchise and broad diagnostics portfolio make Abbott a large incumbent in continuous biosensing, with the channel and regulatory infrastructure to expand into adjacent analytes such as hormones.
- Medtronic: Major medical device incumbent with continuous biosensing capabilities (Guardian CGM) and deep clinical relationships, positioning it as a potential competitor if it extends into hormone monitoring.
- Oura: Smart ring wearable that includes temperature-based cycle and hormonal insights. Comparable as a consumer wearable for women's reproductive health, though uses a different sensing modality.
Emerging players
- Inne: Berlin-based femtech startup developing a saliva-based at-home hormone monitor for cycle tracking. Direct overlap with Level Zero on hormone biosensing for women's health.
- Quanterix: Ultra-sensitive biomarker detection platform (Simoa) with applications in reproductive hormone research. Comparable in underlying biosensing science and clinical research customer base.
Others
- Carrot Fertility: Enterprise fertility benefits platform partnering with clinics and employers. Adjacent rather than directly competitive, but operates in the same IVF/menopause customer ecosystem and could be a distribution or partnership channel.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Level Zero Health social profiles
Digital presenceLevel Zero Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
Level Zero Health leadership team
Management profileNumber of profiles
Profiles12 records
Level Zero Health funding detail
Funding detailFunding overview
Funding rounds2 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Level Zero Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Level Zero Health
What does Level Zero Health do?
Level Zero Health develops a DNA-based biosensor platform that enables real-time, non-invasive hormone monitoring through interstitial fluid analysis. The product consists of a single-use skin-worn patch applied for 10–15 minutes, paired with a compact handheld unit that captures and displays the measurement, covering estradiol (E2), progesterone (P4), luteinising hormone (LH), cortisol, and testosterone with 98% accuracy across the human clinical range. The platform targets IVF clinics, menopause research and management programs, testosterone replacement therapy providers, and research institutions studying hormone biology.
Is Level Zero Health a public or private company?
Level Zero Health is a private company. It is classified as venture growth investor backed and is currently operating.
When was Level Zero Health founded?
Level Zero Health was founded in 2023. It employs 11 to 50 people.
Where is Level Zero Health based?
Level Zero Health is headquartered in London, United Kingdom, in the Europe region.
How does Level Zero Health make money?
Two revenue lines are on record. Hormone Monitoring Patches are the primary driver. The others are real-time Monitoring Platform.
Who are Level Zero Health's main competitors?
Direct peers on record are Dexcom, Mira, Natural Cycles and Modern Fertility. Broad incumbents are Abbott, Medtronic and Oura. Emerging players are Inne and Quanterix. Carrot Fertility is listed as an others.
Does Level Zero Health have an API?
No public API is recorded for Level Zero Health.
What industry is Level Zero Health in?
Level Zero Health's product category is Wearable Hormone Biosensor Diagnostics. Its primary akta.pro industry code is HLAHACAK, Continuous Temperature & Fever Monitoring (Wearable Thermometry). Its NAICS code is 334510 and its SIC code is 2835.